首页> 外文OA文献 >Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas

【2h】

Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas

机译：III期或IV级星形细胞瘤患者中表达EGFRVIII和NY-ESO-1的减毒活单核细胞增生李斯特菌疫苗（ΔactA/ΔinlB）ADU-623的安全性和免疫原性的I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas [J] . Marka Crittenden, Keith S Bahjat, Rui Li, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：III期或IV级星形细胞瘤患者中表达EGFRVIII和NY-ESO-1的减毒单核细胞增生李斯特菌活疫苗（ΔactA/ΔinlB）ADU-623的安全性和免疫原性的I期研究
2. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase i studies of safety and immune induction. [J] . Dung T Le, Dirk G Brockstedt, Ran Nir-Paz, Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第3期

机译：表达减毒活的李斯特菌减毒活疫苗（ANZ-100）和表达间皮素的减毒李斯特菌活疫苗（CRS-207）：安全性和免疫诱导的第一阶段研究。
3. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix [J] . Maciag Paulo Cesar, Radulovic Sinisa, Rothman John Vaccine . 2009,第30期

机译：减毒李斯特菌减毒活疫苗的首次临床应用：Lm-LLO-E7在子宫颈晚期癌患者中的I期安全性研究
4. Phase I study of safety and immunogenicity of ADU-623 a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1 in patients with who grade III/IV astrocytomas [O] . Marka Crittenden, Keith S Bahjat, Rui Li, 2015

机译：III期或IV级星形细胞瘤患者中表达EGFRVIII和NY-ESO-1的减毒活单核细胞增生李斯特菌疫苗（ΔactA/ΔinlB）ADU-623的安全性和免疫原性的I期研究
5. Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623 [O] . 2020

机译：Live-Taveenation histeria单核细胞增生 - 编码EGFRVIII-NY-ESO-1疫苗ADU-623
6. Randomized Double-Blind Phase III Pivotal Field Trial of the Comparative Immunogenicity Safety and Tolerability of Two Yellow Fever 17D Vaccines (ARILVAX(Trademark) and YF-VAX(Trademark)) in Healthy Infants and Children in Peru [R] . Belmusto-Worn, V. E. , Sanchez, J. L. , McCarthy, K. , 2004

机译：秘鲁健康婴儿和儿童两种黄热病17D疫苗（aRILVaX（商标）和YF-VaX（商标））的比较免疫原性安全性和耐受性的随机双盲III期关键现场试验

Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas

著录项

引文网络

相似文献

相关主题

期刊订阅